EDINBURGH, Scotland, May 24, 2023
/PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the
"Company") (NASDAQ: TCBP) a clinical stage biotechnology
company developing platform allogeneic gamma-delta T cell therapies
for cancer, is proud to announce it will be presenting at the LD
Micro Invitational XIII Conference being held at the Luxe Sunset
Boulevard Hotel in Los Angeles, CA
June 6 - 8, 2023.
LD Micro Invitational XIII
Date: June 6 – 8, 2023
Location: Los Angeles, CA
Presentation Time: Wednesday, June 7,
2023 at 2:00 pm ET
(11:00 am PT)
Format: In-person 1x1's and Presentations
Speakers: TC BioPharm Chief Executive Officer, Bryan Kobel
Conference Website: Click here
For more information on the LD Micro Invitational XIII
Conference or to schedule a one-on-one meeting with TC BioPharm
management, please contact your conference representative or you
may also email your request to ir@tcbiopharm.com.
About LD Micro
LD Micro began in 2006 with the sole purpose of being an
independent resource to the microcap world. What started as a
newsletter highlighting unique companies has transformed into the
pre-eminent event platform in the space. For more information,
please visit ldmicro.com.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue. TC BioPharm uses
an allogeneic approach in both unmodified and CAR modified
gamma-delta T cells to effectively identify, target and eradicate
both liquid and solid tumors in cancer.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of
acute myeloid leukemia using the Company's proprietary allogeneic
CryoTC technology to provide frozen product to clinics worldwide.
TC BioPharm also maintains a robust pipeline for future indications
in solid tumors as well as a significant IP/patent portfolio in the
use of CARs with gamma-delta T cells and owns our manufacturing
facility to maintain cost and product quality controls.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-to-present-at-ld-micro-invitational-xiii-conference-on-june-7-2023-301833431.html
SOURCE TC BioPharm